Despite a high P/S ratio, Hebei Changshan Biochemical Pharmaceutical's recent poor growth signals potential investor risk. High P/S ratio, alongside declining revenues, may indicate overvaluation and potential disappointment for shareholders.
The market seems less concerned with EPS decline, focusing more on revenue growth, indicative of trust in the company's possible expansion. The firm's superior total shareholder return, driven by dividends, shows its aptitude for shareholder reward. Recent share price performance suggests improved business momentum, indicating a potentially auspicious investment time.
The company's increased debt, decreased revenue, and negative EBIT and free cash flow are concerning factors. The balance sheet currently appears weak and poses risks to shareholders, necessitating improvements over time.
Hebei Changshan Biochemical Pharmaceuticalに関するコメント
まだコメントはありません